Skip to search formSkip to main contentSkip to account menu

MD6

The MD6 Message-Digest Algorithm is a cryptographic hash function. It uses a Merkle tree-like structure to allow for immense parallel computation of… 
Wikipedia (opens in a new tab)

Related topics

Related topics

13 relations
Buffer overflowComparison of cryptographic hash functionsCryptographic hash functionCycles per byte

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
KI Intolerance Study: A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib (TGR-1202) in Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K…
Background: Although kinase inhibitor (KI) therapies such as ibrutinib are generally well tolerated, intolerance is the most… 
2016
2016
Long-term follow-up of the PI3K{delta} inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and…
7512Background: TGR-1202 is a novel, once-daily PI3Kδ inhibitor with a differentiated safety profile from other PI3Kδ inhibitors… 
2015
2015
Prolonged survival in patients >= 60 years with first relapsed/refractory acute myeloid leukemia treated with vosaroxin plus cytarabine vs placebo plus cytarabine: Results from the phase 3 VALOR…
Author(s): Krug, U; Ravandi, F; Ritchie, EK; Sayar, H; Lancet, JE; Craig, MD; Vey, N; Strickland, SA; Schiller, GJ; Jabbour, E… 
2015
2015
Clinical activity and safety profile of TGR-1202, a novel once daily PI3Kδ inhibitor, in patients with CLL and B-cell lymphoma.
7069 Background: TGR-1202 is a novel, next generation PI3Kδ inhibitor which lacks the hepatotoxicity associated with other PI3K… 
Review
2015
Review
2015
Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial
2014
2014
TGR-1202, a Novel Once Daily PI3Kδ Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma
Background: TGR-1202 is a novel oral, next generation PI3Kδ inhibitor which notably lacks the hepatotoxicity associated with… 
2014
2014
Activity of TGR-1202, a novel once-daily PI3K{delta} inhibitor, in patients with relapsed or refractory hematologic malignancies.
2513 Background: TGR-1202 is a novel, next generation PI3Kδ inhibitor. Preliminary data from an ongoing Ph I study of TGR-1202… 
2009
2009
Linearization Framework for Collision Attacks: Application to CubeHash and MD6
In this paper, an improved differential cryptanalysis framework for finding collisions in hash functions is provided. Its… 
2009
2009
RAM-Based Reconfigurable Implementation of the MD6 Hash Function
Recent breakthroughs in cryptanalysis of standard hash functions like SHA-1 and MD5 raise the need for alternatives. The MD6 hash… 
2005
2005
Assessing quality of life (QL) and patient reported outcomes (PROs) in clinical trials and clinical practice: A study using a hand-held computerized form of the validated LCSS instrument in patients…
8067 Background: Improving survival, QL, and PROs are key goals in cancer treatment. Valid QL instruments are available; however… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)